Wealth Enhancement Advisory Services
AXSM icon

Wealth Enhancement Advisory Services’s Axsome Therapeutics AXSM Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66M Buy
19,919
+739
+4% +$160K 0.01% 1054
2026
Q1 		$3.23M Sell
19,180
-2,578
-12% -$445K 0.01% 1133
2025
Q4 		$3.74M Buy
21,758
+253
+1% +$35.3K 0.01% 1168
2025
Q3 		$2.55M Buy
21,505
+827
+4% +$93.2K ﹤0.01% 1307
2025
Q2 		$2.18M Buy
20,678
+34
+0.2% +$3.6K ﹤0.01% 1314
2025
Q1 		$2.41M Buy
20,644
+1,017
+5% +$116K ﹤0.01% 1152
2024
Q4 		$1.66M Sell
19,627
-181
-0.9% -$16.6K ﹤0.01% 1269
2024
Q3 		$1.78M Buy
19,808
+754
+4% +$65.8K ﹤0.01% 1115
2024
Q2 		$1.53M Buy
19,054
+9
+0% +$666 ﹤0.01% 1097
2024
Q1 		$1.52M Buy
19,045
+130
+0.7% +$10.9K ﹤0.01% 1068
2023
Q4 		$1.51M Buy
+18,915
New +$1.26M ﹤0.01% 1001

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

Wealth Enhancement Advisory Services's AXSM Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Axsome Therapeutics (AXSM) stake by 3.9% in Q2 2026, buying an estimated $160K and bringing the position to 19,919 shares worth $4.66M. The position accounts for 0.01% of the portfolio, ranked #1054.

Wealth Enhancement Advisory Services first reported a position in AXSM in Q4 2023 and has held it in 11 quarters since. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Wealth Enhancement Advisory Services held 19,919 shares of Axsome Therapeutics worth $4.66M as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 739 Axsome Therapeutics shares in Q2 2026, an estimated $160K.
  • Axsome Therapeutics made up 0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #1054 holding.
  • Wealth Enhancement Advisory Services first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.